Literature DB >> 8370576

Relation of cardiovascular risk factors to atherosclerosis in type III hyperlipoproteinemia.

G Feussner1, A Wagner, R Ziegler.   

Abstract

The familial lipoprotein disorder type III hyperlipoproteinemia (HPL) carries a marked increase in the risk of accelerated and premature atherosclerosis, but there is considerable variation among affected individuals in susceptibility to cardiovascular disease (CVD). We studied the influence of independent risk factors for atherosclerosis in 67 patients with clinically overt type III HPL and homozygosity for apolipoprotein (apo) E2. Among the different risk factors (lipid and lipoprotein levels, age, sex, body mass index, smoking status, hypertension, and diabetes mellitus) there was only a statistically significant difference in age between 25 patients with atherosclerosis and 42 patients without atherosclerosis. Serum lipoprotein (a), [Lp, (a)], levels were 30.6% higher in the atherosclerosis group, but this was not statistically significant. We conclude that (in contrast to familial hypercholesterolemia) elevated Lp (a) concentrations may not be regarded as a component of the clinical syndrome of type III HPL.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370576     DOI: 10.1007/bf00219678

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  26 in total

1.  A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM.

Authors:  K BERG
Journal:  Acta Pathol Microbiol Scand       Date:  1963

2.  Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III.

Authors:  G Utermann; K H Vogelberg; A Steinmetz; W Schoenborn; N Pruin; M Jaeschke; M Hees; H Canzler
Journal:  Clin Genet       Date:  1979-01       Impact factor: 4.438

3.  Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3.

Authors:  G R Warnick; C Mayfield; J J Albers; W R Hazzard
Journal:  Clin Chem       Date:  1979-02       Impact factor: 8.327

4.  Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor.

Authors:  J Thiery; V W Armstrong; J Schleef; C Creutzfeldt; W Creutzfeldt; D Seidel
Journal:  Klin Wochenschr       Date:  1988-05-16

5.  Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid.

Authors:  L A Carlson; A Hamsten; A Asplund
Journal:  J Intern Med       Date:  1989-10       Impact factor: 8.989

Review 6.  Apolipoprotein E polymorphism in health and disease.

Authors:  G Utermann
Journal:  Am Heart J       Date:  1987-02       Impact factor: 4.749

7.  Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows.

Authors:  W J Schneider; P T Kovanen; M S Brown; J L Goldstein; G Utermann; W Weber; R J Havel; L Kotite; J P Kane; T L Innerarity; R W Mahley
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

8.  Screening for the apolipoprotein B-100 arginine3500-->glutamine mutation in patients with type III hyperlipoproteinemia.

Authors:  G Feussner; H Schuster
Journal:  Clin Genet       Date:  1992-12       Impact factor: 4.438

9.  Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation.

Authors:  E Boerwinkle; H J Menzel; H G Kraft; G Utermann
Journal:  Hum Genet       Date:  1989-04       Impact factor: 4.132

10.  The relationship of lipoprotein (a) (Lp(a)) to risk factors of coronary heart disease: initial results of the prospective epidemiological study on company employees in Westfalia.

Authors:  H Schriewer; G Assmann; M Sandkamp; H Schulte
Journal:  J Clin Chem Clin Biochem       Date:  1984-09
View more
  6 in total

1.  Severe xanthomatosis associated with familial apolipoprotein E deficiency.

Authors:  G Feussner
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

2.  A 10-bp deletion in the apolipoprotein epsilon gene causing apolipoprotein E deficiency and severe type III hyperlipoproteinemia.

Authors:  G Feussner; J Dobmeyer; H J Gröne; S Lohmer; S Wohlfeil
Journal:  Am J Hum Genet       Date:  1996-02       Impact factor: 11.025

3.  Factors associated with coronary artery calcification in young female patients with SLE.

Authors:  K Manger; M Kusus; C Forster; D Ropers; W G Daniel; J R Kalden; S Achenbach; B Manger
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

4.  Clinical features of type III hyperlipoproteinemia: analysis of 64 patients.

Authors:  G Feussner; A Wagner; B Kohl; R Ziegler
Journal:  Clin Investig       Date:  1993-05

Review 5.  Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia.

Authors:  L Renee Ruhaak; Arnoud van der Laarse; Christa M Cobbaert
Journal:  Ann Clin Biochem       Date:  2019-03-19       Impact factor: 2.057

Review 6.  Cardiovascular disease in diabetes, beyond glucose.

Authors:  Robert H Eckel; Karin E Bornfeldt; Ira J Goldberg
Journal:  Cell Metab       Date:  2021-07-21       Impact factor: 31.373

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.